Altimmune to Participate in the Leerink Global Healthcare Conference
March 03 2025 - 7:30AM
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage
biopharmaceutical company, today announced that members of the
Company’s management team will participate in a fireside chat at
the Leerink Global Healthcare Conference. Details are as follows:
|
Conference: |
Leerink Global
Healthcare Conference |
|
|
|
|
Date/Time: |
Monday, March 10, 2025, at 3:40 p.m. EST |
The session will be webcast and can be accessed
by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage
biopharmaceutical company focused on developing innovative
next-generation peptide-based therapeutics. The Company is
developing pemvidutide, a GLP-1/glucagon dual receptor agonist for
the treatment of obesity and MASH. For more information, please
visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Company Contact:Greg WeaverChief Financial
OfficerPhone: 240-654-1450ir@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke,
BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified
individual.
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2025 to Apr 2025
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2024 to Apr 2025
